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Summary
In the last years, growing attention has been focused
on the vascular component of airway remodelling in
chronic bronchial inflammation, such as asthma and
COPD, and on its role in the progression of disease.
In particular, in asthmatic subjects, the bronchial
mucosa shows a larger number of vessels with high-
er dimension and a greater vascular area. Recently,
insights have been obtained on the pivotal role of
vascular endothelial growth factor (VEGF) in promot-
ing vascular remodelling and angiogenesis. In fact,
many studies conducted on biopsies, induced spu-
tum or BAL, have shown the involvement of VEGF
and of its receptors in the vascular remodelling
processes. However, multiple mechanisms act in
concert in chronic airway diseases, resulting in
bronchial vascular remodelling, with a variety of
growth factors and cytokines involved. Presumably,
the vascular component of airway remodelling is a
complex multi-step phenomenon engaging several
mediators. The aim of this review was to analyze the
morphological aspects of the vascular component of
airway remodelling and the possible mechanisms in-
volved in asthma and COPD.
KEY WORDS: bronchial asthma, COPD, angiogene-
sis, pulmonary vessels, VEGF, airway remodelling,
bronchial microcirculation.
Introduction
It is well known that the functional consequences of in-
flammation on asthma and COPD is the airflow limita-
tion, which can be easily reverted in asthma but not in
COPD. In both diseases, the inflammation is associat-
ed with cellular and structural changes called “remod-
elling”, that may lead to thickening of the airway wall,
thus promoting airway narrowing and airflow limitation
(1, 2). The structural changes characterizing airway re-
modelling include alterations in the composition, size,
mass, number and organization of the cellular and mo-
lecular components of the airway wall. The airways in
the main categories of diseases differ in the nature and
extent of inflammatory cell infiltrate (eosinophils or
neutrophils), degree of gland cell enlargement and
goblet cell hyperplasia, increased smooth muscle
mass, reticular basement membrane thickening, loss
of alveolar attachments, and destructive airspace en-
largement (3-5). In the case of chronic airway dis-
eases, the remodelling accom-
panies with vascular alter-
ation, caused by multiple
mechanisms acting in con-
cert, as growth factors and
cytokines released from
various sites of airway and
vascular walls (6, 7). Most
of the literature regarding
angiogenesis and bronchial
vascular remodelling in
chronic airway inflammation
arises from studies on asthmatic patients (8-12). Inter-
estingly, it has been recently shown that bronchial vas-
cular changes may also occur in COPD (13-15). It is
reported that bronchial microcirculation can develop
qualitative and quantitative alterations such as vasodi-
latation, increased permeability and angiogenesis.
Currently, it is not fully known whether or not these
changes are always present and have a precise tem-
poral sequence. However, microvascular changes in
asthma and COPD may contribute to an increase in
airway wall thickness which may be associated with
disease progression (7). This review focuses on the
morphological aspects of the vascular component in
airway wall remodelling in asthma and COPD.
Angiogenesis and bronchial vascular remodelling
in asthma
Bronchial microvasculature plays several functions
that are essential for maintaining homeostasis. Provi-
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sion of oxygen and nutri-
ents, temperature regula-
tion, humidification of in-
spired air (16) are only
some examples. For this
reason, researchers are fo-
cusing a lot of attention on
the vascular component of
airway remodelling in asthma. There is evidence that
structural vascular changes may significantly occur in
the mucosa of the asthmatic airways. In asthma, the
increase of vessel caliber through vasodilation, togeth-
er with angiogenesis and interstitial edema caused by
microvascular leakage may lead to a change in airway
microvascularity (13, 17, 18). Furthermore, in asthmat-
ic patients the airway microvascularity changes are as-
sociated with an increase in airway blood flow (Qaw)
and blunted β2- adrenergic vasodilator responsive-
ness (19), suggesting the presence of endothelial dys-
function whose role in the pathogenesis of bronchial
asthma is not clear yet (20, 21). In asthmatic airways,
a link between airway inflammation and changes in mi-
crovascularity has been suggested (22, 23). Many me-
diators and growth factors which are directly related to
airway inflammation in asthma, such as histamine, the
major preformed mast cell mediator, prostaglandins,
leukotrienes, and cytokines, seem to be also involved
in the induction of vascular responses, such as angio-
genesis, vasodilation and microvascular leakage (24,
25). However, this interpretation mostly derives from in
vitro studies or from studies on model animals. The on-
ly growth factor whose role has been established
through in vivo and asthmatic airway studies is the
Vascular Endothelial Growth Factor (VEGF). VEGF is
a potent multifunctional cytokine with several important
effects on vascularity such as acting on angiogenic
sprouting as well as on vascular leakage and perme-
ability (26). Hoshino et al. (18) showed that the levels
of three angiogenic factors, VEGF, basic fibroblast
growth factor (bFGF), and angiogenin were significant-
ly increased in the airways of asthmatic subjects com-
pared to controls. Moreover, the authors found a signif-
icant correlation between microvascularity and the
amount of angiogenic factors. Another interesting find-
ing of this in vivo study was that in the submucosa the
cells resulting positive to angiogenic factors were
CD34+, eosinophils, and macrophages (27). These re-
sults were successively confirmed by Chetta et al. (28).
In their study authors showed that biopsy specimens of
bronchial mucosa of patients with mild-to-moderate
asthma had an upregulation of VEGF expression of
compared to controls (28). They also found that VEGF
was related to the number of vessels and to the thick-
ness of the basement membrane (28). Using colocal-
ization analysis, they showed that main cellular source
of VEGF were mast cells, thus supporting the idea
these cells, though release of VEGF, contribute to the
angiogenesis process in asthma. Mast cells are a het-
erogeneous group of cells and can be divided into two
groups depending on the protease enzymes that ex-
press: only tryptase or only chymase, and tryptase plus
chymase. In asthmatic subjects, it has demonstrated
that about the 25% of mast cells expresses only chy-
mase (29). Another interesting finding obtained with
colocalization analysis on the bronchial mucosa
showed a close relationship between chymase positive
mast cells and VEGF (29), suggesting that chymase
positive mast cells may play a role in the vascular com-
ponent of airway remodelling in asthma. It has been
suggested that remodelling process might be benefi-
cial in airway disease and that airway wall-thickening
protects against airway narrowing and air trapping by
making the airway wall stiffer (30). However, the detri-
mental effects seem to be more important than the pro-
tective ones. It is well known that remodelling may in-
crease the irreversible component of airway obstruc-
tion, accelerate the decline in pulmonary function, and
facilitate the persistence of airway hyperresponsive-
ness, the loss of smooth muscle stretch relaxation, the
increase in contractile response, and the loss of elas-
tic recoil (3). The clinical relevance of airway vascular
remodelling remains to be determined. The results
concerning the effects of airway microvascularity on
clinical features and pulmonary function in asthma are
still scarce. In literature, some studies (10, 13, 25)
showed a direct relationship between an increase in
microvascularity, expressed as the density of vessels,
and the severity of asthma. In this sense, the airway
wall of severe asthmatics was more vascularized than
that of mild-to-moderate patients. Orsida et al. (31), in
a study including patients both having and not having
steroid treatment, showed that the vessels density was
weakly related to bronchial hyperresponsiveness to
methacholine, and that vessel density was greater in
those patients with the most marked hyperresponsive-
ness. In the same study he also showed a significant
positive correlation between percentage change in
forced expiratory volume in the 1st second (FEV1) af-
ter bronchodilator and number of vessels/mm2 for the
asthma patients overall. Taken together these findings
suggest that the increased microvascularity may have
pathophysiological relevance in asthma. Another no-
table result derives from the study by Hashimoto et al.
(13), in which the relative impact of the increased mi-
crovascularity of medium and small airways on airflow
limitation was assessed in nine asthmatic patients who
underwent lobectomy or pneumonectomy for a solitary
peripheral carcinoma. In this study it was found that
the FEV1, expressed as a percentage of predicted val-
ue, had a positive correlation with the vascularity in the
inner area of the medium airways, but not of the small
ones. Even though correlation does not imply causali-
ty, however the results of the Hashimoto study seem to
support the idea that the enhanced vascularity of the
medium airways contributes to airflow limitation in pa-
tients with asthma. Ricciardolo et al. (32) recently re-
marked the role of VEGF, investigating the expression
of bradykinin receptors in bronchial biopsies of asth-
matic and COPD patients, the association with angio-
genic factors, and the capability of bradykinin to re-
lease VEGF. The expression of bradykinin receptors
was found to be positively correlated to vascular re-
modelling in asthma, suggesting a role for bronchial
asthmatic fibroblasts in releasing vascular growth fac-
A. Zanini et al.
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tors (VEGF and angiogenin) upon activation of
bradykinin receptors (32).
Angiogenesis and bronchial vascular remodelling
in COPD
The structural changes that characterize COPD re-
modelling are epithelial damage, mucus gland hyper-
plasia, subepithelial collagen deposition, increased
smooth muscle, and vascular alterations (3). Different-
ly to asthma, in COPD the vascular airway remodelling
seems to be less represented as well as angiogenesis.
The in vivo studies concerning vascular changes of the
bronchial wall in COPD airways show dissimilar re-
sults. Kuwano et al. (33) in their work did not find any
significant difference in vascular area between mild
COPD patients and controls. On the other hand, more
recent studies by Hashimoto et al. (13), Calabrese et
al. (14), and Zanini et al. (15) have shown an increase
of the vascular area of the airway wall in COPD pa-
tients. In particular, Hashimo-
to et al. (13) showed that in
COPD patients the vascular
area was increased in the
small airways, but not in the
medium airways and no
correlation was found be-
tween the degree of vascu-
larity and airflow limitation.
In his study, Calabrese et
al. (14) examined mucosal
microvascularity in large air-
ways of current COPD smok-
ers finding a significant difference in their vascular
area compared to controls. Even in this study no cor-
relation between microvascularity data and clinical and
functional data was observed, as well as between
symptomatic smokers with normal function and symp-
tomatic smokers with moderate COPD. Overall, the au-
thors showed that the increase of the bronchial vascu-
larity was associated with higher cellular expression of
VEGF and vascular expression of αvβ3 integrin (14).
αvβ3 integrin is an adhesion molecule that is upregu-
lated in new vessel proliferation in response to angio-
genic stimuli, while it is downregulated or absent on
resting endothelium (34). Zanini et al. (15) assessed
bronchial vascular remodelling in the central airways of
COPD patients and showed that in these subjects the
bronchial vascular area and vessel size were in-
creased. Furthermore, they observed an increased ex-
pression of VEGF, bFGF, and transforming growth fac-
tor-beta (TGF-β) in COPD patients, as compared to
controls, providing the evidence of the strong relation
between the vascular component of airway remodel-
ling and the bronchial expression of VEGF and TGF-β.
Supporting these research, Soltani et al. (35) have
shown that airway remodelling in smokers and in pa-
tients with mild-to-moderate COPD was associated
with fragmentation of the reticular basement mem-
brane and altered distribution of vessels in the airway
wall. The COPD patients, both current smokers and
ex-smokers, had a major fragmentation and splitting of
the reticular membrane compared to healthy nonsmok-
ers. Also the number of vessels staining for VEGF in
the reticular basement membrane was higher in both
groups of COPD patients, compared to healthy non-
smokers and these morphological features may have
potential physiological consequences in COPD. In that
study (35), the authors found that in current smokers
with COPD, VEGF vessel staining positively correlated
with FEV1, expressed as percent of predicted value.
Similarly to what was found in asthmatic airways,
VEGF also seems to be a protein crucially involved in
the vascular remodelling of COPD. In a more recent
work, the same group observed that also mast cells
(36) and TGF-β1 activity (37) are involved in the in-
creased angiogenesis in the reticular basement mem-
brane in COPD patients. Kranenburg et al. (38)
showed that COPD airways had a higher expression of
VEGF in several cell populations, such as in the
bronchial, bronchiolar, and alveolar epithelium and in
bronchiolar macrophages, as well as airway smooth
muscle and vascular smooth muscle cells in both the
bronchiolar and alveolar regions. They also found that
the expression of VEGF in bronchial mucosal mi-
crovessels and airway smooth muscle cells, bronchio-
lar epithelium, and medial vascular smooth muscle
cells of larger pulmonary arteries associated with bron-
chiolar airways was inversely related to FEV1. Al-
though association does not establish causality, taken
together, these findings strongly suggest a role for
VEGF in airway and vascular remodelling, and thereby
in the development of airway obstruction in COPD.
Vascular structural changes in airway mucosa of
COPD patients do not seem to imply any quantitative
change in Qaw, even if qualitative changes may occur.
Also in this case there is a difference between asthma
and COPD: while in asthmatic patients Qaw levels
were increased (19), patients with COPD may show
normal Qaw levels. Qaw was measured in age-
matched healthy current smokers, healthy ex-smokers,
ex-smokers with COPD, and healthy lifetime nonsmok-
ers and it did not significantly differ among groups (39).
The authors also found that Salbutamol inhalation in-
creased Qaw significantly in lifetime nonsmokers and
healthy ex-smokers, but not in healthy current smokers
and ex-smokers with COPD (39). Similar results were
found by Paredi et al. (40), who showed that Qaw was
similar in patients with COPD compared to controls,
and that, after inhalation of 200 mcg of Salbutamol, it
was significantly higher in controls. Both these studies
(39, 40) demonstrate that cigarette smoking as well as
COPD are associated with a lower vasodilator re-
sponse to inhaled Salbutamol, and that this may be in-
terpreted as an expression of endothelial dysfunction.
More recently, our group hypothesized that the in-
creased vascularity and angiogenic factors in the cen-
tral airways of COPD patients may impact on the mat-
uration of dendritic cells (DCs) (41). In bronchial biop-
sies from large airways of COPD patients, we showed
a reduced maturation of DCs, that was strictly associ-
ated with the number of vessels and the expression of
angiogenic factors such as VEGF and TFG-β, suggest-
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ing that angiogenesis in the airway wall might be asso-
ciated with altered trafficking of DCs in the lungs (41).
Significance of the vascular component of airway
remodelling
It is well known that changes in bronchial microvascula-
ture may result in airway wall thickening and in the re-
duction of the luminal area.
Several studies in asthma
and COPD showed a signif-
icant correlations between
the morphological or biolog-
ical data (number of ves-
sels, vascular area, expres-
sion of angiogenic factors)
and lung function parame-
ters, such as FEV1 (13, 27,
31, 38, 42, 43), and airway hyperresponsiveness (31,
42). The functional effects of vascular remodelling may
be amplified by pre-existing airway wall architecture
modifications, such as bronchial mucosal thickening,
cellular infiltration, collagen deposition and bronchial
smooth muscle changes (16, 44). The thickening of
each of the three layers composing the airway wall can
have a different effect on its functionality (44). The thick-
ening of the inner airway wall layer (epithelium, lamina
reticularis, and loose connective tissue between the
lamina reticularis and the airway smooth muscle (ASM)
layer) can lead to the amplification of the effect of ASM
shortening; the thickening of the outer (or adventitial)
layer could decrease the static and dynamic loads on
the ASM; and an increase in the ASM layer thickness
can increase the strength of the muscle. Also the remod-
elling of the connective tissue in the smooth muscle
compartment could vary the
amount of radial constraint
provided to the ASM, and the
thickening and fibrous con-
nective tissue deposition in
all layers could decrease air-
way distensibility and allow
ASM adaptation in shorter
lengths (44). Hypertrophy
and hyperplasia of mucous
glandular structures and loss
of alveolar attachments are
considered to be the main structural changes of airway
remodelling in COPD and they may play a key role in the
functional effects of airway remodelling (45). Lastly, we
can here only point out the important role of small air-
ways. Despite a considerable amount of interest in small
airways disease since the 1960s, these airways remain
a difficult area to study because of their relative inacces-
sibility and lack of a readily available, reproducible, and
noninvasive technique to assess their function (5, 46).
However, in COPD patients the exact explanation for
the link between structural airway changes, with partic-
ular reference to the vascular component, and the func-
tional and clinical consequences are not yet clearly de-
fined and further studies are needed.
Conclusions
In the last two decades, researchers have put a lot of
effort in the investigation of the microvascular changes
happening in bronchial airway mucosa during chronic
inflammation, such as asthma and COPD. Up to now,
most of the studies have been focused on asthma,
while less work has been done in COPD. For this rea-
son it is necessary to better differentiate the effects of
smoking on bronchial microvascularity from the specif-
ic changes due to airflow obstruction. Although there
are evidences suggesting that vessel changes in the
bronchial wall happen both in asthma and COPD,
these two diseases have distinct alterations. In fact,
while angiogenesis seems to be a typical feature of
asthma, in COPD little evidence supports the view that
vasodilatation is prevalent. Microvascular changes in
the bronchial airway mucosa are probably the conse-
quence of the action of many angiogenic factors, and
VEGF seems to be most involved in asthma and
COPD, and different types of cells can play a role as
the source of VEGF. The clinical and functional effects
of the vascular remodelling still need to be determined
both in asthma and COPD, even if some reports sug-
gest that the vascular component of airway remodel-
ling may contribute to worsening of airway function.
There are few data regarding the effects of current
therapies on bronchial vascular remodelling. Some
longitudinal studies conducted on asthma, using biop-
sy quantification of vascular changes, showed that in-
haled corticosteroids could effectively act on vascular
remodelling in asthmatic airways, partially reversing
microvascular changes. In COPD, evidence from a
cross-sectional study suggests also that long-term
treatment with inhaled corticosteroids is associated
with a decrease in airway microvascularity. A more
specific knowledge about angiogenic processes and
their consequences in the airway wall both in asthma
and especially COPD are urgently needed, as well as
new therapeutic strategies for these conditions.
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